NYSE : GSK

GSK plc

$51.98 USD

$0.63 (1.23%)

Volume
5.48M
Average Volume
4.03M
Market Capitalization
$104.87B
P/E Ratio
13.52
Dividend Yield
3.42%
Price Target
$53.00
Year High
$61.70
Year Low
$36.75
Day High
—
Day Low
—
Payout Ratio
$0.45
Current Ratio
$0.79
Company Overview

NYSE

Luke Victor Miels

Drug Manufacturers - General

Healthcare

GSK

66841

GB

USD

https://www.gsk.com

44 20 8047 5000

37733W204

0001131399

Liquidity Metrics

1.07

0.79

0.52

0.15

0.45

Sales & Valuation

$32.67B

2.40

4.42

15.64

2.50

Profitability

$5.56

$5.72B

17.78%

22.69%

35.78%

9.27%

P/E Metrics

13.52

0.15

0.15

Analyst Price Target & Rating

$53.00

$85.00

$35.25

Buy

4/5

29 Analysts

-1.92%

Financial Health Scores

1.67

7/9

-$6.16B

$82.91B

$59.93B

$8.13B

Key Metrics (TTM)

$93.6B

2.86

8.09

0.79

35.78%

13.76%

7.44%

6.44%

$12.03

-248 days

Company Executives
Name Title
Constantin Fest Senior Vice President & Head of Investor Relations
Shobie Ramakrishnan Chief Digital & Technology Officer
Luke V. Miels Chief Executive Officer & Director
David Simon Redfern President of Corporate Development
James Ford Senior Vice President & Group General Counsel of Legal & Compliance
Tony Wood Chief Scientific Officer and Head of R&D
Jesse L. Goodman Scientific & Medical Expert
Emma Natasha Walmsley Executive Officer
Julie Brown Chief Financial Officer & Executive Director
Roanne Parry Chief People Officer
Poll Results

No votes yet today — be the first to share your view!

About GSK plc (NYSE:GSK) Stock

GSK plc, a global pharmaceutical entity founded in 1715 and headquartered in Brentford, United Kingdom, dedicates its efforts to the research, development, and manufacturing of a wide array of medical solutions. Until May 2022, the company was known as GlaxoSmithKline plc. Its primary objective is to prevent and treat illnesses by producing both vaccines and a comprehensive range of specialty and general medicines for markets across the United Kingdom, the United States, and internationally. The company's operations are organized into two key divisions: Commercial Operations and Total R&D. Its extensive vaccine portfolio includes immunizations against shingles, meningitis, respiratory syncytial virus (RSV), seasonal and pandemic influenza, and polio. Beyond preventative care, GSK provides ... diverse therapeutic products covering critical areas such as HIV, oncology, respiratory and immunology conditions, and other specialized medical fields. This also encompasses inhaled treatments for chronic respiratory ailments like asthma and chronic obstructive pulmonary disease (COPD), along with antibiotics for various infections. Innovation at GSK is frequently driven by strategic partnerships. Notable collaborations include an agreement with CureVac to advance mRNA-based influenza vaccines, and alliances with Wave Life Sciences and Elsie Biotechnologies focused on developing oligonucleotide platforms. Furthermore, GSK has established two distinct strategic collaborations with Relation to progress therapeutics for fibrotic diseases and osteoarthritis. The company is also engaged in a multi-target strategic alliance aimed at developing pioneering treatments for individuals suffering from Parkinson's disease, and a partnership with Flagship Pioneering to identify novel medicines and vaccines.

Bank of New York Mellon Corp Reduces Holdings in GSK PLC Sponsored ADR $GSK

2026-07-25 04:05:37

Bank of New York Mellon Corp lowered its position in GSK PLC Sponsored ADR (NYSE: GSK) by 13.8% during the first quarter, according to its most recent filing with the SEC. The institutional investor owned 808,139 shares of the pharmaceutical company's stock after selling 129,449 shares during the period. Bank of New York

FTSE 100 shares to watch: Lloyds, Barclays, IAG, NatWest, GSK, AstraZeneca

2026-07-24 04:07:00

The FTSE 100 Index was little changed this week as investors assessed the escalating UK-Iran crisis, the ongoing US earnings season, and a series of key UK economic releases. Market participants digested the latest jobs, inflation, and retail sales data for July, all of which could influence the Bank of England's next policy decision.

SMMT Shares Updated Ivonescimab Survival Data From NSCLC Study

2026-07-23 11:36:25

Summit announces updated HARMONi overall survival data and partners with Arcus to test ivonescimab in kidney cancer, expanding its late-stage development.

GSK Lands FDA Approval for Nuvalent-Acquired Jideytro for NSCLC

2026-07-23 11:36:16

GSK secures early FDA approval for Jideytro, its first lung cancer therapy, backed by strong ARROS-1 data, and strengthens its precision oncology portfolio.

Will GSK's Specialty Medicines Boost Q2 Revenue Growth?

2026-07-23 10:11:08

GSK's Specialty Medicines unit is expected to post double-digit CER growth in Q2, driven by newer HIV, RI&I and oncology drugs despite legacy pressures.

Jideytro (zidesamtinib) approved in the US for previously treated ROS1-positive non-small cell lung cancer

2026-07-22 13:58:00

Approval based on ARROS-1 phase I/II trial demonstrating meaningful and durable responses in patients with locally advanced or metastatic disease1 Next-generation design aims to address key efficacy and tolerability challenges of treating ROS1-positive NSCLC GSK's first approval in lung cancer, part of a growing portfolio of targeted treatments LONDON, July 22, 2026 /PRNewswire/ -- GSK plc (LSE/NYSE: GSK) today announced the US Food and Drug Administration (FDA) has approved Jideytro (zidesamtinib), a ROS1 selective inhibitor, for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who received a prior ROS1 kinase inhibitor.1 The approval comes ahead of the original target action date of 18 September 2026 and follows the FDA's Breakthrough Therapy and Orphan Drug Designations.2 Jideytro, part of the portfolio from the recently completed acquisition of Nuvalent, Inc. 3, was developed to address key efficacy and/or tolerability challenges of treating ROS1-postive NSCLC. Its next-generation design aims to combine high target-selectivity, broad coverage of ROS1 resistance mutations and blood-brain barrier penetration to address disease in the brain.

US FDA approves GSK's lung cancer drug

2026-07-22 12:31:49

GSK said ​on ‌Wednesday the ​U.S. ​FDA has approved ⁠its ​drug ​for adults with ​a ​form of lung ‌cancer ⁠who have previously ​received ​a ⁠targeted ​therapy.

GSK (GSK) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

2026-07-21 11:00:47

Glaxo (GSK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Frequently Asked Questions

What is the current GSK plc (GSK) stock price?

GSK plc(NYSE:GSK) stock price is $51.98 in the last trading session. During the trading session, GSK stock reached the peak price of $61.7 while $36.75 was the lowest point it dropped to. The percentage change in GSK stock occurred in the recent session was 1.23% while the dollar amount for the price change in GSK stock was $0.63.

GSK's industry and sector of operation?

The NYSE listed GSK is part of Drug Manufacturers - General industry that operates in the broader Healthcare sector.

Who are the executives of GSK?

Constantin Fest | Senior Vice President & Head of Investor Relations
Shobie Ramakrishnan | Chief Digital & Technology Officer
Luke V. Miels | Chief Executive Officer & Director
David Simon Redfern | President of Corporate Development
James Ford | Senior Vice President & Group General Counsel of Legal & Compliance

How many employees does GSK have?

Number of GSK employees currently stands at 66841. GSK operates from 79 New Oxford Street, London, GL WC1A 1DG, GB.

Link for GSK official website?

Official Website of GSK is: https://www.gsk.com

How do I contact GSK?

GSK could be contacted at phone #44 20 8047 5000 and can also be accessed through its website. GSK operates from 79 New Oxford Street, London, GL WC1A 1DG, GB.

How many shares of GSK are traded daily?

The average number of GSK shares traded daily for last 3 months was 4.03M.

What is the market cap of GSK currently?

The market value of GSK currently stands at $104.87B with its latest stock price at $51.98